Maya Martinez-Davis
Corporate Officer/Principal presso GSK PLC
Profilo
Maya Martinez-Davis is currently the President-US Pharmaceuticals at GSK Plc.
Prior to this, she was the Independent Director at Mirati Therapeutics, Inc. from 2018 to 2024 and the President-Biopharma Latin America at Merck KGaA from 2016 to 2019.
She completed her undergraduate degree at St. Louis University and her graduate degree at Instituto de Empresa SL.
Posizioni attive di Maya Martinez-Davis
| Società | Posizione | Inizio |
|---|---|---|
| GSK PLC | Corporate Officer/Principal | 01/01/2020 |
Precedenti posizioni note di Maya Martinez-Davis
| Società | Posizione | Fine |
|---|---|---|
| MIRATI THERAPEUTICS | Director/Board Member | 23/01/2024 |
| MERCK KGAA | Corporate Officer/Principal | 01/08/2019 |
Formazione di Maya Martinez-Davis
| St. Louis University | Undergraduate Degree |
| Instituto de Empresa SL | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| MERCK KGAA | Health Technology |
| GSK PLC | Health Technology |
| Aziende private | 1 |
|---|---|
Mirati Therapeutics, Inc.
 Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
- Borsa valori
- Insiders
- Maya Martinez-Davis
